Symposium to discuss nanotechnology's contribution to theragnostics
As part of a $4.5 million, nine-year effort to employ molecular imaging and nanotechnology in developing “theragnosis”—simultaneous diagnostics and therapeutics—partnering research teams from Purdue University’s Discovery Park and the Korean Institute of Science and Technology will hold a daylong symposium, Sept. 6, in West Lafayette, Ind.
Jonng Joo Na, CEO of DKC in South Korea, will deliver the keynote address, “Technology Commercialization of Optical Imaging Probes,” according to a release.
The symposium is the sixth since the bi-national partnership launched in 2006. The partnership focuses more than a dozen Korean and Purdue researchers on expanding the role of nanoparticles in the diagnosis and treatment of cancer or chronic diseases like diabetes and multiple sclerosis.
Discovery Park is a $375 million, 40-acre interdisciplinary and multidisciplinary research and education complex located on Purdue University’s West Lafayette campus.
Jonng Joo Na, CEO of DKC in South Korea, will deliver the keynote address, “Technology Commercialization of Optical Imaging Probes,” according to a release.
The symposium is the sixth since the bi-national partnership launched in 2006. The partnership focuses more than a dozen Korean and Purdue researchers on expanding the role of nanoparticles in the diagnosis and treatment of cancer or chronic diseases like diabetes and multiple sclerosis.
Discovery Park is a $375 million, 40-acre interdisciplinary and multidisciplinary research and education complex located on Purdue University’s West Lafayette campus.
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.